ASX All Ords lithium stock Wildcat Resources Ltd (ASX: WC8) has more than doubled in value over the past 12 months.

Wildcat Resources shares were recently trading for 40 cents apiece, which sees the share price up a whopping 109.0% since this time last year.

For some context, the All Ordinaries Index (ASX: XAO) was recently up a rather meagre 0.8% over this same period.

Investors have been bidding up the ASX All Ords lithium stock as its Western Australian Tabba Tabba lithium project progresses towards production.

Wildcat will also have attracted attention amid the past year’s 79% increase in global spodumene (a lithium bearing ore) prices.

And looking ahead, Dolphin Partners Financial Services’ Arthur Garipoli believes the company is well-placed to deliver more outperformance (courtesy of The Bull).

Should I buy the ASX All Ords lithium stock today?

Citing the first reason he’s bullish on Wildcat Resource shares, Garipoli said:

This Western Australian explorer is advancing the Tabba Tabba Lithium-Tantalum project, which is a large-scale, hard rock development in an established mining jurisdiction with low sovereign risk and close to Port Hedland infrastructure.

The second reason you might want to buy the ASX All Ords lithium stock today is that, while the share price is up 109% since this time last year, the Wildcat share price has fallen more than 36% since closing at 63 cents on 18 June.

“The recent share price fall may represent a good entry opportunity for investors looking for a recovery in lithium markets and in a company with near term catalysts,” Garipoli noted.

There are also a number of upcoming catalysts that could help support further gains in the Wildcat share price.

Garipoli concluded:

WC8 has completed a pre-feasibility study. A large resource base and an upcoming definitive feasibility study de-risks the company. In our view, WC8 represents a compelling risk-reward scenario.

What’s the latest from Wildcat Resources?

Wildcat Resources released its June quarter update on 29 July.

The ASX All Ords lithium stock cited “significant advancement” across its Pilbara lithium portfolio. That included accelerated development activities at Tabba Tabba, with promising exploration results continuing to come in from the miner’s nearby Bolt Cutter lithium discovery.

Commenting on the Tabba Tabba project, Wildcat management noted:

At Tabba Tabba, the Definitive Feasibility Study (DFS) progressed across all major technical disciplines including mine planning, metallurgy, process engineering, infrastructure design, environmental approvals and project financing.

Optimisation work undertaken during the quarter identified opportunities to improve project economics through modifications to the proposed mine schedule, earlier expansion of processing capacity and incorporation of additional mineral resources that were not considered in the Preliminary Feasibility Study.

Metallurgical programs continued to demonstrate robust concentrate quality and recoveries, while engineering design advanced toward completion.

The post Up 109%! 3 reasons this ASX All Ords lithium stock is still a buy today appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Centuria Industrial REIT, Endeavour, Wildcat Resources shares
• Experts name 3 ASX shares to buy this week

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It was a busy week for Australia’s top brokers. This has led to a number of broker notes being released. 

Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:

DigiCo Infrastructure REIT (ASX: DGT)

According to a note out of Bell Potter, its analysts have retained their buy rating on this data centre company’s shares with a trimmed price target of $3.35. The broker highlights that DigiCo announced its FY 2026 result last week with its underlying EBITDA of $126.6 million slightly above expectations. And while guidance for FY 2027 EBITDA came in below estimates, it believes a material capex spend and customer letters of intent points to earnings ramping up in FY 2028 as billing comes on line. It believes this should support a growing dividend. In addition, with its shares still trading at a deep discount to their net tangible assets, Bell Potter sees a lot of value in them. The DigiCo share price ended the week at $2.53.

Goodman Group (ASX: GMG)

A note out of Macquarie reveals that its analysts have retained their outperform rating and $35.40 price target on this industrial property company’s shares. This follows the release of an FY 2026 result that revealed operating earnings marginally ahead of consensus estimates. Once again, while its guidance for FY 2027 was a touch short of expectations, the broker appears confident it can outperform this and is expecting a double-digit three-year earnings compound annual growth rate. So, with its shares trading at a discount to its long-run PE ratio, Macquarie thinks now could be the  time to buy. The Goodman share price was fetching $27.27 at Friday’s close.

Megaport Ltd (ASX: MP1)

Analysts at Morgans have upgraded this network services company’s shares to a buy rating with a $25.00 price target. According to the note, Megaport delivered both FY 2026 earnings and FY 2027 guidance that were above market expectations. This reflects record network and compute growth. And while there are minor balance sheet concerns, Morgans believes the company will end FY 2027 with surplus liquidity of nearly $600 million. Outside this, it highlights that deals already contracted suggest that EBITDA will lift 3 times in FY 2027 and then more than double in FY 2028. The Megaport share price ended the week at $18.38.

The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

More reading

• Why Megaport, Lendlease and JB Hi-Fi shares all crashed 14% to 15% this week
• 8 ASX shares just upgraded by the experts
• 3 ASX shares UBS says will return better than 36%
• Buy, hold, sell: Fortescue, Northern Star, and Megaport shares
• Why were Goodman shares just downgraded?

Motley Fool contributor James Mickleboro has positions in Goodman Group and Megaport. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, Macquarie Group, and Megaport. The Motley Fool Australia has recommended Goodman Group and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX 200 healthcare shares vastly outperformed their peers, rising 9.21%, as earnings season continued last week.

Pleasing FY26 reports from heavyweights CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME) turbocharged the sector.

The broader S&P/ASX 200 Index (ASX: XJO) slipped 0.62% over the week to 9,058.9 points on Friday.

Healthcare is in the middle of a rapid recovery following a 29% slump over the 12 months to early June.

The S&P/ASX 200 Health Care Index (ASX: XHJ) reached a 9-year low on 3 June.

The sector then pivoted as value investors rushed in to snap up blue-chips on the cheap.

Healthcare shares have skyrocketed 41% since 3 June, compared to a 3% rise for the ASX 200.

Let’s review some specifics from last week.

Healthcare shares led the ASX sectors last week

Last week, several major healthcare companies revealed their latest periodic earnings results.

The CSL share price leapt 23.3% to $168.30 on the strength of its FY26 results last week.

CSL shares have rocketed 82% since the healthcare sector rebound began on 3 June.  

Pro Medicus shares jumped 7.1% to $191.60 on the back of the company’s FY26 report.

The Pro Medicus share price is up 20% since 3 June. 

The Cochlear Ltd (ASX: COH) share price rose 1.4% to $135.48 following the hearing implant maker’s FY26 report.

Cochlear shares have increased 42% since 3 June.

The Healius Ltd (ASX: HLS) share price jumped 13.8% to 46 cents following its FY26 report last week.

Healius shares are up 38% since 3 June.

The EBOS Group Ltd (ASX: EBO) share price ascended 7.2% to $18.96 following the company’s FY26 results.

EBOS shares are up 20% since 3 June.

The Mesoblast Ltd (ASX: MSB) share price lifted 6.8% to $2.36 following a phase 3 trial update.

Mesoblast shares have risen 17% since 3 June.  

ASX 200 market sector snapshot

Here’s how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

S&P/ASX 200 market sector	Change last week
Healthcare (ASX: XHJ)	9.21%
Materials (ASX: XMJ)	5.61%
Energy (ASX: XEJ)	3.5%
Utilities (ASX: XUJ)	0.85%
Communication Services (ASX: XTJ)	(1.41%)
Industrials (ASX: XNJ)	(2.08%)
Consumer Staples (ASX: XSJ)	(2.65%)
Information Technology (ASX: XIJ)	(3.57%)
A-REIT (ASX: XPJ)	(4.43%)
Financials (ASX: XFJ)	(5.11%)
Consumer Discretionary (ASX: XDJ)	(6.55%)

The post ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 16 ASX 200 shares with ex-dividend dates next week
• 3 ASX 200 stocks, including CSL, leaping 15% to 23% in this week’s sliding market
• 8 ASX shares just upgraded by the experts
• Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Cochlear, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.